Screener
Charles River Laboratories CRL DSA — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|
| Cash flows relating to operating activities | ||
| Net income (loss) | $(15,562) | $78,571 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Depreciation and amortization | 134,441 | 239,871 |
| Long-lived asset impairments | 26,279 | 31,203 |
| Stock-based compensation | 42,162 | 30,184 |
| Deferred income taxes | 12,077 | (41,030) |
| Write down of inventories | 3,165 | 11,067 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's DSA — D&A?
- Charles River Laboratories (CRL) reported DSA — D&A of $41.63M in Q2 2026.
- How has Charles River Laboratories's DSA — D&A changed year-over-year?
- Charles River Laboratories's DSA — D&A decreased by 2.2% year-over-year, from $42.58M to $41.63M.
- What is the long-term trend for Charles River Laboratories's DSA — D&A?
- Over 2 years (2023 to 2025), Charles River Laboratories's DSA — D&A has grown at a -0.2% compound annual growth rate (CAGR), from $174.72M to $174.03M.
- What does DSA — D&A mean?
- The total non-cash expense representing the wear and tear of physical assets and the expiration of intangible assets. It is a key adjustment when calculating cash flow from operations.
Ask your AI about Charles River Laboratories's dsa — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude